(Q37629050)

English

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

scientific article published on 16 August 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study) (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

0 references

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

Takayuki Takahama

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Kazuko Sakai

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Masayuki Takeda

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Koichi Azuma

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Toyoaki Hida

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Masataka Hirabayashi

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Tetsuya Oguri

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Hiroshi Tanaka

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Noriyuki Ebi

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Toshiyuki Sawa

10

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Akihiro Bessho

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Motoko Tachihara

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Hiroaki Akamatsu

13

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Shuji Bandoh

14

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Daisuke Himeji

15

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Tatsuo Ohira

16

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Mototsugu Shimokawa

17

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Yoichi Nakanishi

18

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Kazuhiko Nakagawa

19

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Kazuto Nishio

20

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

0 references

publication date

16 August 2016

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

36

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

58492-58499

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

23 August 2017

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

6 September 2017

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5295446

1 September 2018

Identifiers

10.18632/ONCOTARGET.11303

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37629050&oldid=1515659882"